{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:43:16Z","timestamp":1790613796444,"version":"4.1.0"},"reference-count":180,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G.A029.11N"],"award-info":[{"award-number":["G.A029.11N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The introduction of highly potent direct\u2010acting antivirals (DAAs) has revolutionized hepatitis C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the era of DAA treatment, because of the high associated costs, high numbers of undiagnosed patients, high re\u2010infection rates in some risk groups and suboptimal drug efficacies associated with host and viral factors as well as advanced stages of liver disease. A correct determination of the HCV genotype allows administration of the most appropriate antiviral regimen. Additionally, HCV genetic sequencing improves our understanding of resistance\u2010associated variants, either naturally occurring before treatment, acquired by transmission at HCV infection, or emerging after virological failure. Because treatment response rates, and the prevalence and development of drug resistance variants differ for each DAA regimen and HCV genotype, this review summarizes treatment opportunities per HCV genotype, and focuses on viral genetic sequencing to guide clinical decision making. Although approval of the first pan\u2010genotypic DAA\u2010only regimen is expected soon, HCV genetic sequencing will remain important because when DAA therapies fail, genotyping and resistance testing to select a new active DAA combination will be essential. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/rmv.1895","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T08:23:05Z","timestamp":1468311785000},"page":"408-434","source":"Crossref","is-referenced-by-count":44,"title":["Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time"],"prefix":"10.1002","volume":"26","author":[{"given":"Lize","family":"Cuypers","sequence":"first","affiliation":[{"name":"KU Leuven \u2013 University of Leuven Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini\u2010Silberstein","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine and Surgery University of Rome Tor Vergata  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"Van Laethem","sequence":"additional","affiliation":[{"name":"KU Leuven \u2013 University of Leuven Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdi","family":"Li","sequence":"additional","affiliation":[{"name":"KU Leuven \u2013 University of Leuven Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology  Leuven Belgium"},{"name":"Department of Metabolism and Endocrinology, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases The Second Xiangya Hospital, Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Mieke","family":"Vandamme","sequence":"additional","affiliation":[{"name":"KU Leuven \u2013 University of Leuven Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology  Leuven Belgium"},{"name":"Center for Global Health and Tropical Medicine, Microbiology Unit Institute for Hygiene and Tropical Medicine, University Nova de Lisboa  Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen Kurt","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"Department of Medicine I University Hospital Bonn  Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1258\/095646204322637182"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2013.10.021"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7092857"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.107"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-4-201202210-00004"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.004"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.021"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25800"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/764540"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.004"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000005"},{"key":"e_1_2_7_18_1","unstructured":"AASLD recommendations for testing managing and treating hepatitis C. The Liver Meeting2015 San Francisco CA November 13\u201017 2015."},{"key":"e_1_2_7_19_1","unstructured":"EASL Recommendation on Treatment of Hepatitis C.http:\/\/www.easl.eu\/medias\/cpg\/HEPC\u20102015\/Full\u2010report.pdf."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-296"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50106"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr215"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit226"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.795543"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i47.8940"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i11.2902"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","unstructured":"KwoP GitlinN NahassR et al.A phase 3 randomized open\u2010label study to evaluate the efficacy and safety of 8 and 12\u2009weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment\u2010na\u00efve and \u2010experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST\u20101. 50thEASL Vienna Austria April 22\u201026 2015. Abstract LP14.","DOI":"10.1016\/S0168-8278(15)30168-9"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","unstructured":"LawitzE MatusowG DeJesusE et al.A phase 3 open\u2010label single\u2010arm study to evaluate the efficacy and safety of 12\u2009weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment\u2010na\u00efve or \u2013experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST\u20102. 50thEASL Vienna Austria April 22\u201026 2015. Abstract LP04.","DOI":"10.1016\/S0168-8278(15)30158-6"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.027"},{"key":"e_1_2_7_36_1","first-page":"219A","article-title":"Safety and efficacy of sofosbuvir\u2010containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jensen DM","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_37_1","first-page":"220A","article-title":"Evaluation of sofosbuvir and simeprevir\u2010based regimens in the TRIO network: academic and community treatment of a real\u2010world, heterogeneous population","volume":"60","author":"Dieterich D","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_38_1","unstructured":"GilmoreJ LynnK BreenD et al.Effectiveness of sofosbuvir\/simeprevir for HIV\/HCV patients in clinical practice. 22ndCROI Feb 23\u201026 2015 Seattle Washington."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"e_1_2_7_41_1","doi-asserted-by":"crossref","unstructured":"PoordadF SchiffER VierlingJM et al.Daclatasvir sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or post\u2010transplant recurrence: ALLY\u20101 phase 3 study. 50thEASL Vienna Austria April 22\u201326 2015. Abstract L08.","DOI":"10.1016\/S0168-8278(15)30154-9"},{"key":"e_1_2_7_42_1","doi-asserted-by":"crossref","unstructured":"WelzelTM HerzerK FerenciP et al.Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. 50th EASL Vienna Austria April 22\u201326 2015. Abstract P0772.","DOI":"10.1016\/S0168-8278(15)30975-2"},{"key":"e_1_2_7_43_1","doi-asserted-by":"crossref","unstructured":"De LedinghenV FontaineH DorivalC et al.Safety and efficacy of sofosbuvir\u2010containing regimens in the French observational cohort ANRS CO22 HEPATHER. 50thEASL Vienna Austria April 22\u201326 2015. Abstract P0795.","DOI":"10.1016\/S0168-8278(15)30998-3"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep\/2016.01.029"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.06.004"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_7_49_1","doi-asserted-by":"crossref","unstructured":"BuggischP PetersenJ WursthornK et al.Real\u2010world effectiveness of ledipasvir\/sofosbuvir 8\u2009weeks chronic hepatitis C treatment. 50thEASL Vienna Austria April 22\u201326 2015. Abstract LP32.","DOI":"10.1016\/S0168-8278(15)30186-0"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28292"},{"key":"e_1_2_7_51_1","first-page":"240A","article-title":"High efficacy of sofosbuvir\/ledipasvir for the treatment of HCV genotype 1 in patients coinfected with HIV on and off antiretroviral therapy: results from the NIAID ERADICATE trial","volume":"60","author":"Townsend KS","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1222"},{"key":"e_1_2_7_54_1","first-page":"239A","article-title":"An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir\/sofosbuvir with or without ribavirin","volume":"60","author":"Bourli\u00e8re M","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_55_1","first-page":"1271A","article-title":"Ledipasvir\/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease\u2010inhibitor based triple therapy","volume":"60","author":"Bourli\u00e8re M","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"e_1_2_7_57_1","doi-asserted-by":"crossref","unstructured":"SamuelD MannsM FornsX et al.Ledipasvir\/sofosbuvir with ribavirin is safe in >600 decompensated and post\u2010liver transplantation patients with HCV infection: an integrated safety analysis of the SOLAR\u20101 and SOLAR\u20102 trials. 50thEASL Vienna Austria April 22\u201326 2015. Abstract G02.","DOI":"10.1016\/S0168-8278(15)30977-6"},{"key":"e_1_2_7_58_1","unstructured":"AfdhalN BaconB DieterichDT et al.Failure with all\u2010oral DAA regimens: real\u2010world experience from the TRIO network. HepDART Wailea Maui Hawaii December 6\u201310 2015. Abstract 59."},{"key":"e_1_2_7_59_1","unstructured":"HinrichsenH WedemeyerH ChristensenS et al.Real\u2010world safety and effectiveness of ombitasvir\/paritaprevir\/r with dasabuvir and\/or ribavirin in the German hepatitis C registry. 51st EASL Barcelona Spain April 13\u201317 2016. Abstract GS07"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_7_66_1","unstructured":"FeldJJ;MorenoC TrinhR et al.TURQUOISE\u2010III: safety and efficacy of 12\u2010week ribavirin\u2010free treatment for patients with HCV genotype 1b and cirrhosis. ISVHLD2015 Berlin Germany June 26 2015."},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.10.019"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27113"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.018"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ381"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"e_1_2_7_72_1","doi-asserted-by":"crossref","unstructured":"KwoP GaneE PengCY et al.Efficacy and safety of grazoprevir\/elbasvir +\/\u2212 RBV for 12\u2009weeks in patients with HCV G1 or G4 infection who previously failed peginterferon\/RBV: C\u2010EDGE treatment\u2010experienced trial. 50thEASL Vienna Austria April 22\u201326 2015. Abstract P0886.","DOI":"10.1016\/S0168-8278(15)31088-6"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.009"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00114-9"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_2_7_77_1","unstructured":"JacobsonIM LawitzE KwoPY et al.An integrated analysis of 402 compensated cirrhotic patients with HCV genotype (GT) 1 4 or 6 infection treated with grazoprevir\/elbasvir. AASLD San Francisco 2015. Abstract 42."},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"e_1_2_7_80_1","unstructured":"JacobsonIM AgarwalK WillemsB et al.High efficacy of sofosbuvir\/velpatasvir across 7 HCV genotypes and 46 subtypes: pooled data from the ASTRAL phase 3 studies. HepDART Wailea Maui Hawaii December 6\u201310 2015. Abstract P109."},{"key":"e_1_2_7_81_1","doi-asserted-by":"crossref","unstructured":"WylesD BrauN KottililS et al.Sofosbuvir\/velpatasvir fixed dose combination for 12\u2009weeks in patients co\u2010infected with HCV and HIV\u20101: the phase 3 ASTRAL\u20105 study. 51stEASL Barcelona Spain April 13\u201317 2016. Abstract PS104.","DOI":"10.1016\/S0168-8278(16)00129-X"},{"key":"e_1_2_7_82_1","doi-asserted-by":"crossref","unstructured":"KwoP PoordadF PorcallaA et al.Safety of ABT\u2010493 and ABT\u2010530 co\u2010administered in patients with HCV genotype 1\u20136 infection: results from the SURVEYOR\u2010I and SURVEYOR\u2010II studies. 51stEASL Barcelona Spain April 13\u201317 2016. Abstract SAT\u2010239.","DOI":"10.1016\/S0168-8278(16)01579-8"},{"key":"e_1_2_7_83_1","doi-asserted-by":"crossref","unstructured":"GaneE PoordadF AsatryanA et al.High efficacy and favorable safety of ABT\u2010493 and ABT\u2010530 co\u2010administration for 12\u2009weeks in HCV genotype 1\u2010infected patients with cirrhosis (SURVEYOR\u2010I). 51stEASL Barcelona Spain April 13\u201317 2016. Abstract SAT\u2010135.","DOI":"10.1016\/S0168-8278(16)01475-6"},{"key":"e_1_2_7_84_1","unstructured":"PoordadF FelizartaF WangS et al.High SVR rates with the combination of ABT\u2010493\u2009+\u2009ABT\u2010530 for 8\u2009weeks in non\u2010cirrhotic patients with HCV genotype 1 or 2 infection. 51stEASL Barcelona Spain April 13\u201317 206. Abstract SAT\u2010157."},{"key":"e_1_2_7_85_1","doi-asserted-by":"crossref","unstructured":"PoordadF GordonSC AsatryanA et al.High efficacy of ABT\u2010493 and ABT\u2010530 in HCV genotype 1 infected patients who have failed direct\u2010acting antiviral\u2010containing regimens: the MAGELLAN\u2010I study. 51stEASL Barcelona April 13\u201317 2016. Abstract GS11.","DOI":"10.1016\/S0168-8278(16)01668-8"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.043"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7734"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62483-1"},{"key":"e_1_2_7_91_1","unstructured":"WelzelTM NelsonDR MorelliG et al.Safety and efficacy of sofosbuvir and ribavirin for the treatment of HCV genotype 2 and 3: results of the HCV\u2010TARGET study. AASLD San Francisco 2015. Abstract 1057."},{"key":"e_1_2_7_92_1","first-page":"1380A","article-title":"Sofosbuvir in combination with PegIFN and ribavirin for 12\u2009weeks provides high SVR rates in HCV\u2010infected genotype 2 or 3 treatment\u2010experienced patients with and without compensated cirrhosis: results from the LONESTAR\u20102 study","volume":"58","author":"Lawitz E","year":"2013","journal-title":"Hepatology"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867321666131228222215"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_7_95_1","unstructured":"SulkowskiMS BrauN LawitzE et al.A randomized controlled trial of sofosbuvir\/GS\u20105816 fixed dose combination for 12\u2009weeks compared to sofosbuvir with ribavirin for 12\u2009weeks in genotype 2 HCV infected patients: the phase 3 ASTRAL\u20102 study. AASLD San Francisco 2015. Abstract 2015."},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26905"},{"key":"e_1_2_7_97_1","unstructured":"H\u00e9zodeC De LedinghenV FontaineH et al. ANRS CO22\u2010Hepather cohort. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. 50thEASL Vienna Austria April 22\u201326 2015."},{"key":"e_1_2_7_98_1","unstructured":"LeroyV AngusP BronowickiJ\u2010P et al.All\u2010oral treatment with daclatasvir plus sofosbuvir plus ribavirin for 12 or 16\u2009weeks in HCV genotype 3\u2010infected patients with advanced fibrosis or cirrhosis: the ALLY\u20103+ phase 3 study. HepDART Wailea Maui Hawaii December 6\u201310 2015. Abstract P126."},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.06.014"},{"key":"e_1_2_7_100_1","unstructured":"GaneEJ HylandRH AnD et al.High efficacy of LDV\/SOF regimens for 12\u2009weeks for patients with HCV genotype 3 or 6 infection. 65thAnnual Meeting of the American Association for the Study of Liver disease November 7\u201311 2014 Boston USA0 Abstract LB\u201011."},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"e_1_2_7_102_1","unstructured":"MangiaA RobertsSK PiankoS et al.Sofosbuvir\/GS\u20105816 fixed dose combination for 12\u2009weeks compared to sofosbuvir with ribavirin for 24\u2009weeks in genotype 3 HCV infected patients: the randomized controlled phase 3 ASTRAL\u20103 study. AASLD San Francisco 2015. Abstract 249."},{"key":"e_1_2_7_103_1","doi-asserted-by":"crossref","unstructured":"KwoPY WylesDL WangS et al.100% SVR4 with ABT\u2010493 and ABT\u2010530 with or without ribavirin in treatment\u2010na\u00efve HCV genotype 3\u2010infected patients with cirrhosis. 51st EASL Barcelona Spain April 13\u201317 2016. Abstract LB01.","DOI":"10.1016\/S0168-8278(16)00170-7"},{"key":"e_1_2_7_104_1","doi-asserted-by":"crossref","unstructured":"MuirAJ StrasserE WangS et al.High SVR rates with ABT\u2010493\u2009+\u2009ABT\u2010530 co\u2010administered for 8\u2009weeks in non\u2010cirrhotic patients with HCV genotype 3 infection. 51st EASL Barcelona Spain April 13\u201317 2016. Abstract PS098.","DOI":"10.1016\/S0168-8278(16)01700-1"},{"key":"e_1_2_7_105_1","doi-asserted-by":"crossref","unstructured":"FosterG GaneE AsatryanA et al.ENDURANCE\u20103: a phase 3 randomized open\u2010lable active\u2010controlled study to compare efficacy and safety of ABT\u2010493\/ABT\u2010530 to sofosbuvir co\u2010administered with daclatasvir in adults with HCV genotype 3 infection. 51st EASL Barcelona Spain April 13\u201317 2016. Abstract THU\u2010482.","DOI":"10.1016\/S0168-8278(16)00366-4"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000516"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.044"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.023"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"e_1_2_7_110_1","doi-asserted-by":"crossref","unstructured":"AsselahT HassaneinTI QaqishRB et al.Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir co\u2010administered with ribavirin in adutls with genotype 4 chronic hepatitis C infection and cirrhosis (AGATE\u2010I). AASLD San Francisco 2015. Abstract 714.","DOI":"10.1016\/S0168-8278(15)31524-5"},{"key":"e_1_2_7_111_1","doi-asserted-by":"crossref","unstructured":"EsmatGE DossWH QaqishRB et al.Efficacy and safety of co\u2010formulated ombitasvir\/paritaprevir\/ritonavir with ribavirin in adults with chronic HCV genotype 4 infection in Egypt (AGATE\u2010II). AASLD San Francisco 2015. Abstract 708.","DOI":"10.1016\/S0168-8278(15)31530-0"},{"key":"e_1_2_7_112_1","doi-asserted-by":"crossref","unstructured":"AbergelA Loustaud\u2010RattiV MetivierS et al.Ledipasvir\/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. 50thEASL Vienna Austria April 22\u201326 2015. Abstract O056.","DOI":"10.1016\/S0168-8278(15)30070-2"},{"key":"e_1_2_7_113_1","first-page":"321A","article-title":"All\u2010oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial","volume":"60","author":"Kapoor R","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_7_114_1","unstructured":"AsselahT ReesinkHW GerstoftJ et al.High efficacy of grazoprevir and elbasvir with or without ribavirin in 103 treatment\u2010na\u00efve and experienced patients with HCV genotype 4 infection: a pooled analysis. AASLD San Francisco 2015. Abstract 251."},{"key":"e_1_2_7_115_1","doi-asserted-by":"crossref","unstructured":"GaneE LalezariJ AsatryanA et al.100% SVR4 and favorable safety of ABT\u2010493\u2009+\u2009ABT\u2010530 administered for 12\u2009weeks in non\u2010cirrhotic patients with genotype 4 5 or 6 infection (SURVEYOR\u2010I). 51stEASL Barcelona Spain April 13\u201317 2016. Abstract SAT\u2010137. e1002832.","DOI":"10.1016\/S0168-8278(16)01477-X"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.003"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2013.06.002"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.9.3127-3134.2002"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01982-06"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.04.005"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.03.006"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27895"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.6.900"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2000.00208.x"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2980.2011.00496.x"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26544"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02035-8"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.02.011"},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000544"},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27934"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00998-15"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep20310"},{"key":"e_1_2_7_133_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002832"},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.06.029"},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01452-09"},{"key":"e_1_2_7_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.07.016"},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.021"},{"key":"e_1_2_7_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature15711"},{"key":"e_1_2_7_140_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501291c"},{"key":"e_1_2_7_141_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00253-11"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02494-12"},{"key":"e_1_2_7_143_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06169-11"},{"key":"e_1_2_7_144_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01390-15"},{"key":"e_1_2_7_145_1","unstructured":"GaneEJ HylandRH YangY et al.Sofosbuvir\/GS\u20105816+GS\u20109857 for 6 or 8\u2009weeks in genotype 1 or 3 HCV\u2010infected patients. AASLD San Francisco 2015. Abstract 38."},{"key":"e_1_2_7_146_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_7_147_1","unstructured":"WatabeT KorenagaM SugiyamaM et al.Distribution of pre\u2010existing NS5A\/NS5B resistance associated variants in genotype 1b patients with hepatitis C virus and response to direct acting antivirals. AASLD San Francisco 2015. Abstract 1795."},{"key":"e_1_2_7_148_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu697"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27375"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_7_151_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02579-13"},{"key":"e_1_2_7_152_1","unstructured":"SorboMC AntonucciFP ManuelliM et al.Different prevalence of HCV resistance and HCV RNA quantification within tumoral and non tumoral liver tissues in HCC\/transplanted patients. 51st EASL Barcelona Spain April 13\u201317 2016. Abstract THU\u2010255"},{"key":"e_1_2_7_153_1","unstructured":"KaganRM LeakeJA.Prevalence of HCV NS3 and NS5A resistance\u2010associated variants (RAVs) in a US reference laboratory database in the era of 2ndgeneration DAAs. HepDART Wailea Maui Hawaii December 6\u201310 2015. Abstract 87."},{"key":"e_1_2_7_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.01.003"},{"key":"e_1_2_7_155_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134395"},{"key":"e_1_2_7_156_1","doi-asserted-by":"crossref","unstructured":"SvarovskaiaE HedskogC MartinR et al.Prevalence of pre\u2010treatment NS5A and NS5B resistance associated variants and genetic variation with HCV subtypes across different countries. 50th EASL Vienna2015; PO894.","DOI":"10.1016\/S0168-8278(15)31097-7"},{"key":"e_1_2_7_157_1","unstructured":"ReddyKR BeaversKL GordonS et al.Effect of baseline factors on response to the fixed\u2010dose combination of daclatasvir (DCV) asunaprevir (ASV) and beclabuvir (BCV) in non\u2010cirrhotic patients with HCV genotype 1 infection. 50th EASL Vienna2015; PO889."},{"key":"e_1_2_7_158_1","unstructured":"FouratiS H\u00e9zodeC SoulierA et al.HCV resistance to daclatasvir\/sofosbuvir across different genotypes in the real life. CROI Boston Massachusetts USA February 22\u201325 2016. Abstract 577."},{"key":"e_1_2_7_159_1","doi-asserted-by":"crossref","unstructured":"SarrazinC Dvory\u2010SobolH SvarovskaiaES et al.The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir\/sofosbuvir +\/\u2212 RBV. 50th EASL Vienna2015; PO773.","DOI":"10.1016\/S0168-8278(15)30976-4"},{"key":"e_1_2_7_160_1","unstructured":"ZeuzemS MizokamiM PiankoS et al.Prevalence of pre\u2010treatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV\/SOF. AASLD San Francisco 2015. Abstract 91."},{"key":"e_1_2_7_161_1","doi-asserted-by":"crossref","unstructured":"LawitzE FlammS YangJC et al.Retreatment of patients who failed 8 or 12\u2009weeks of ledipasvir\/sofosbuvir\u2010based regimens with ledipasvir\/sofosbuvir for 24\u2009weeks. 50th EASL Vienna2015; O005.","DOI":"10.1016\/S0168-8278(15)30012-X"},{"key":"e_1_2_7_162_1","doi-asserted-by":"crossref","unstructured":"CharltonM MannsM Dvory\u2010SobolH et al.Resistance analyses for ledipasvir\/sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post liver transplant (SOLAR\u20101 & 2 studies). 51stEASL Barcelona Spain April 13\u201317 2016. Abstract PS099.","DOI":"10.1016\/S0168-8278(16)01701-3"},{"key":"e_1_2_7_163_1","unstructured":"JacobsonI.Prevalence and impact of baseline NS5A resistance associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection. AASLD. San Francisco 2015. Abstract LB22."},{"key":"e_1_2_7_164_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv564"},{"key":"e_1_2_7_165_1","unstructured":"ZhdanovK.Sofosbuvir plus ribavirin for the treatment of Russian patients with chronic HCV genotype 1 or 3 infection. APASL2015 March 12\u201315 Istanbul."},{"key":"e_1_2_7_166_1","first-page":"77","article-title":"and the European HIV Drug Resistance Guidelines Panel. European recommendations for the clinical use of HIV drug resistance testing: 2011 update","volume":"13","author":"Vandamme AM","year":"2011","journal-title":"AIDS Reviews"},{"key":"e_1_2_7_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.10.010"},{"key":"e_1_2_7_168_1","doi-asserted-by":"crossref","unstructured":"KrishnanP TripathiR SchnellG et al.Long\u2010term follow\u2010up of treatment\u2010emergent resistance\u2010associated variants in NS3 NS5A and NS5B with paritaprevir\/r\u2010 ombitasvir\u2010 and dasabuvir\u2010based regimens. 50th EASL Vienna2015; O057.","DOI":"10.1016\/S0168-8278(15)30071-4"},{"key":"e_1_2_7_169_1","doi-asserted-by":"crossref","unstructured":"BlackS PakI IngravalloP et al.Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevir\/elbasvir +\/\u2212 ribavirin: the C\u2010worthy study. 50th EASL Vienna2015; P0891.","DOI":"10.1016\/S0168-8278(15)31094-1"},{"key":"e_1_2_7_170_1","doi-asserted-by":"crossref","unstructured":"Dvory\u2010SobolH WylesD OuyangW et al.Long\u2010term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. 50th EASL Vienna2015; O059.","DOI":"10.1016\/S0168-8278(15)30073-8"},{"key":"e_1_2_7_171_1","unstructured":"VermehrenJ SusserS DietzJ et al.Retreatment of patients who failed DAA\u2010combination therapies: real\u2010world experience from a large hepatitis C resistance database. 51stEASL Barcelona Spain April 13\u201317 2016. Abstract PS103."},{"key":"e_1_2_7_172_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ874"},{"key":"e_1_2_7_173_1","unstructured":"H\u00e9zodeC FouratiS ScoazecG et al.Retreatment of HCV DAA failures: HCV infection may be incurable. 51stEASL Barcelona Spain April 13\u201317 2016. Abstract THU\u2010217."},{"key":"e_1_2_7_174_1","unstructured":"PoordadF BennettM SepeTE et al.Retreatment of HCV genotype 1 DAA\u2010failures with ombitasvir\/paritaprevir\/r dasabuvir and sofosbuvir. AASLD San Francisco 2015. Abstract LB\u201020."},{"key":"e_1_2_7_175_1","unstructured":"LawitzE.C\u2010SWIFT retreatment: 12\u2009weeks of elbasvir\/grazoprevir with sofosbuvir and ribavirin successfully treated GT1\u2010infected subjects who failed short\u2010duration all\u2010oral therapy. AASLD San Francisco 2015. Abstract LB\u201012."},{"key":"e_1_2_7_176_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7122941"},{"key":"e_1_2_7_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.06.013"},{"key":"e_1_2_7_178_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.010"},{"key":"e_1_2_7_179_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32836381cc"},{"key":"e_1_2_7_180_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00812.x"},{"key":"e_1_2_7_181_1","unstructured":"HillA SimmonsB SaleemJ et al.Five\u2010year risk of late relapse or reinfection with hepatitis C after sustained virological response: meta\u2010analysis of 49 studies in 8534 patients. 22ndCROI Seattle WA February 23\u201326 2015. Abstract 654."}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frmv.1895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Frmv.1895","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.1895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T19:22:29Z","timestamp":1694114549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.1895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":180,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/rmv.1895"],"URL":"https:\/\/doi.org\/10.1002\/rmv.1895","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"value":"1052-9276","type":"print"},{"value":"1099-1654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]}}}